Target intelligence / Profile preview

HLA class I histocompatibility antigen, alpha chain E (HLA-E)

Target
HLA-E
Molecular classification
Receptor, Other
01

Overview

HLA class I histocompatibility antigen, alpha chain E (HLA-E), functionally homologous to mouse Histocompatibility 2, T region locus 23 (H2-T23, encoding Qa-1b), is a non-classical MHC class Ib molecule. Unlike classical MHC class I molecules, HLA-E exhibits very limited polymorphism and primarily presents conserved signal sequence-derived peptides (such as VL9) to the inhibitory receptor CD94/NKG2A expressed on natural killer (NK) cells and CD8+ cytotoxic T lymphocytes. This interaction delivers a strong inhibitory signal that prevents immune-mediated lysis of healthy cells. However, many cancers overexpress HLA-E to exploit this pathway, effectively evading immune surveillance and resisting T-cell and NK-cell-mediated destruction. Consequently, the HLA-E/NKG2A axis has emerged as a major immune checkpoint and a highly promising therapeutic target in oncology. While clinical-stage antibodies like monalizumab target the NKG2A receptor, novel preclinical agents such as the monoclonal antibodies 3H4v31 and 4D7 directly target HLA-E or specific HLA-E/peptide complexes to block this inhibitory interaction and promote tumor clearance, sometimes additionally triggering antibody-dependent cellular cytotoxicity (ADCC).

Other names
Histocompatibility 2, T region locus 23H2-T23Qa-1Qa-1bQa1Qed-1T23bT23dMHC class I antigen Qa1H-2 class I histocompatibility antigen, D-37 alpha chainMHC class I antigen E
02

Mechanism of action

Immune checkpoint inhibition by blocking the interaction between HLA-E and the inhibitory receptor CD94/NKG2A on NK cells and CD8+ T cells, thereby restoring antitumor immune responses and potentially inducing antibody-dependent cellular cytotoxicity (ADCC) against HLA-E-expressing tumor cells.

03

Biological functions

Immune responseSignal transductionOther
04

Disease associations

CancerInfectionInflammationOther
05

Safety considerations

Autoimmunity and loss of self-tolerance due to HLA-E expression on healthy tissuesToxicity to normal cells expressing HLA-EPotential for systemic inflammatory response or cytokine release syndromeImpairment of maternal-fetal tolerance during pregnancy
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

HLA-E expression level on tumor cellsNKG2A expression on tumor-infiltrating lymphocytesSoluble HLA-E (sHLA-E) levelsCD8+ T cell infiltrationNK cell infiltration

Beyond the preview

Go deeper on HLA class I histocompatibility antigen, alpha chain E (HLA-E).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class I histocompatibility antigen, alpha chain E (HLA-E).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call